A Vision for the Future of Science Philanthropy
By Evan S. Michelson and Adam F. Falk,
Issues in Science and Technology
| 11. 09. 2021
Although we can envision many ways that the scientific enterprise might evolve in the future, an often-overlooked component will surely play an essential role: science philanthropy. By this we mean the provision of charitable giving for science or technology research by individual donors or foundations. As Robert Conn, past president and chief executive officer of The Kavli Foundation, details in his overview of the emergence of philanthropic giving for research, science philanthropy has always played a critical and leading role in America’s approach to research and development, with a history that predates much of the federal funding apparatus.
Today, the landscape of science philanthropy is rapidly changing. It consists of both established and newer foundations, a constellation of institutions including organizations with an illustrious history of giving for research as well as entities created more recently. Collectively, science philanthropy accounts for at least $2 billion in annual support for research. If we include spending from university endowments that supports research at those institutions, the total impact of philanthropy on science is estimated to be as much as $20 billion per...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...